Our Targeted Anti c-Kit Antibody
Briquilimab (formerly JSP191) is a targeted anti c-Kit monoclonal antibody designed to deplete diseased mast and stem cells as well as enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.
Jasper is studying briquilimab across multiple diseases. Briquilimab is currently being studied as a targeted conditioning agent for severe combined immunodeficiency (SCID), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Fanconi Anemia (FA) and Sickle Cell Disease (SCD). Jasper will also be starting studies of briquilimab as a chronic therapeutic in patients with Chronic Urticaria and Low to Intermediate Risk MDS.